Best of ASCO - 07/19/22 - Lung Cancer Living Room™

Join host Danielle Hicks, the Chief Patient Officer at GO2 Foundation for Lung Cancer, as she has a detailed and exciting discussion in this month's episode of the Lung Cancer Living Room, as she explores some of the most-discussed topics related to clinical trials for new targeted therapies related to specific biomarkers at this year's 2022 ASCO conference with Dr. David Carbone, the director of the James Thoracic Center at The Ohio State University Wexner Medical Center. They discuss new therapies and related trials designed for specific subtypes of well-known biomarkers such as KRAS and EGFR. In addition, Dr. Carbone shares exciting new findings in the CheckMate 816 study related to using specific targeted drugs as both neoadjuvant and adjuvant therapies before and after surgical resections, with results that seem promising. With new targeted therapies being used in exciting trials such as adagrasib in the KRYSTAL-1 trial, and amivantamab in the CHRYSALIS-2 trial, this episode is proof of the inspiring amount of new drugs being developed and innovative new approaches being used in the fight against lung cancer.